Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152256 | 0.79 | CNR2 (0.61) | NPC1RAB9AMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4879959 | 0.78 | KDM4E (0.59) | KDM4ENPC1RAB9AMAPTKMT2A | |
| SCHEMBL3367624 | 0.76 | HPGD (0.49) | NPC1RAB9AMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL12017943 | 0.76 | NPC1 (0.60) | NPC1RAB9AMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4175248 | 0.75 | KDM4E (0.56) | KDM4EMAPTKMT2AHSD11B1ALDH1A1 | |
| SCHEMBL4175247 | 0.71 | KDM4E (0.51) | KDM4EMAPTKMT2AMAPK1LMNA | |
| SCHEMBL4882901 | 0.71 | GAA (0.57) | NPC1RAB9AMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4879094 | 0.70 | KDM4E (0.44) | KDM4EMAPTLMNAL3MBTL1HPGD | |
| SCHEMBL716311 | 0.70 | KDM4E (0.44) | KDM4EMAPTHSD11B1ALDH1A1TRPV4 | |
| SCHEMBL713590 | 0.70 | KDM4E (0.44) | KDM4EHSD11B1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120052057-A9 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2012-03-01 | — | — | US | claimed |
| US-20110150859-A1 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2011-06-23 | — | — | US | claimed |
| EP-2140029-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | Biotie Therapies Corp. (FI) | 2010-01-06 | — | — | EP | claimed |
| WO-2008125738-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-23 | — | — | WO | claimed |
| US-20120052057-A9 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2012-03-01 | — | — | US | disclosed |
| US-20110150859-A1 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2011-06-23 | — | — | US | disclosed |
| EP-2140029-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | Biotie Therapies Corp. (FI) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008125738-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | KDM4E 1548/4885BDKRB1 91/4885NPC1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.